Edwards Lifesciences Corporation logo EW - Edwards Lifesciences Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 32
HOLD 16
SELL 0
STRONG
SELL
0
| PRICE TARGET: $98.09 DETAILS
HIGH: $110.00
LOW: $85.00
MEDIAN: $95.00
CONSENSUS: $98.09
UPSIDE: 6.15%

About Edwards Lifesciences Corporation (https://www.edwards.com)

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Key Executives

NAME TITLE DOB SALARY
Bernard J. Zovighian Chief Executive Officer & Director 1968 $3,788,122 USD
Scott Ullem Corporate Vice President & Chief Financial Officer 1967 $1,845,590 USD
Theodora Mistras Corporate Vice President & Chief Financial Officer 1982 $1,845,590 USD
Annette Maria Bruls Corporate Vice President of EMEA, Canada, & Latin America 1971 $1,627,873 USD
Donald E. Bobo Jr. Corporate Vice President of Strategy & Corporate Development 1962 $1,595,262 USD
Daveen Chopra Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies 1979 $1,555,892 USD
Andrew Dahl Principal Accounting Officer, Senior Vice President & Corporate Controller 1978
Christine Z. McCauley Corporate Vice President of Human Resources 1965
Dirksen J. Lehman Corporate Vice President of Public Affairs
Gary I. Sorsher Senior Vice President of Quality & Regulatory Compliance 1965
Joseph Nuzzolese Corporate Vice President of Global Operations & Quality
Mark D. Peterson Corporate Vice President & General Counsel 1963
Snehashish Sarkar Senior VP and Chief Information & Digital Officer 1975
Todd Brinton FACC Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer
Wayne T. Markowitz GM & Senior VP of Surgical Structural Heart 1973

Company Peers

Peer analysis pending, check back in 1-2 minutes.